Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose dobutamine and single-dose tocilizumab in acute myocardial infarction at high risk of cardiogenic shock
2021-002028-19Phase 2Active
- Sponsor
- Department of Cardiology, Rigshospitalet
- Start
- Aug 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dobutamine and tocilizumab in myocardial infarction (MI) (4 arms), sponsored by Department of Cardiology, Rigshospitalet. Primary endpoint: NT-proBNP. Started Aug 2021; status: active.
02
Drugs
dobutaminetocilizumab
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on 2021-002028-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002028-19.